Eledon Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Eledon Pharmaceuticals, Inc. on July 2, 2021, regarding events occurring on July 1, 2021. The company is incorporated in Delaware and its common stock trades on the Nasdaq Capital Market under the symbol "ELDN".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The primary material change reported is the appointment of Jan Hillson, M.D., to the Board of Directors. The Board determined that Dr. Hillson qualifies as an "independent" director under applicable Nasdaq Marketplace Rules.
Compensatory Arrangements and Contingencies
- Stock Option Grant: In connection with her appointment, Dr. Hillson was granted an option to purchase up to 40,000 shares of Common Stock at an exercise price of $7.68 per share.
- Vesting Schedule: The option vests in two tranches: 20,000 shares on the first anniversary of the grant date and the remaining 20,000 shares on the second anniversary.
- Indemnification: Dr. Hillson entered into the company's standard indemnification agreement. Eledon may be required to indemnify her for certain expenses, including attorneys' fees, judgments, fines, and settlement amounts incurred in actions arising from her service as a director.
Investor Verification Checklist
- Verify the independence status of Dr. Hillson under current Nasdaq rules.
- Review the total number of outstanding stock options and the dilution impact of the 40,000-share grant.
- Confirm the terms of the standard indemnification agreement to understand potential liability exposure.
- Check for any subsequent filings regarding the vesting or exercise of the granted options.